This work seeks to advance quantitative methods for biomolecular design, especially for predicting biomolecular interactions, via a focused series of community blind prediction challenges. Physical methods for predicting binding free energies, or ?free energy methods?, are poised to dramatically reshape early stage drug discovery, and are already finding applications in pharmaceutical lead optimization. However, performance is unreliable, the domain of applicability is limited, and failures in pharmaceutical applications are often hard to understand and fix. On the other hand, these methods can now typically predict a variety of simple physical properties such as solvation free energies or relative solubilities, though there is still clear room for improvement in accuracy. In recent years, competitions and crowdsourcing have proven an effective model for driving innovations in diverse fields. In our field, blind prediction challenges have played a key role in driving innovations in prediction of physical properties and binding, especially in the form of the SAMPL series of challenges. Here, we will continue and extend SAMPL prediction challenges to include new physical properties, more complicated host-guest binding data, and application to biomolecular systems. Carefully selected systems and novel experimental data will provide challenges of gradually increasing complexity spanning between systems which are now tractable to those which are marginally out of reach of today's methods but still slightly simpler than those covered by the Drug Design Data Resource (D3R) series of challenges on existing pharmaceutical data. We will work with D3R to run blind challenges on the data we generate and to ensure it is designed to maximally benefit the field. In our original proposal, Aim 4 focused on using data generated in a SAMPL series of challenges, applying proven crowdsourcing-based techniques to drive the development of new methods and new understanding of the strengths and weaknesses of existing techniques. Here, we extend this work by building out software infrastructure for a fully automated component of these challenges, where workflow components can be deposited in a common registry and then linked together to automate participation in SAMPL challenges. This solves several key problems at once, and will allow innovations resulting from the SAMPL challenges to have much greater impact on the community and much more rapidly disseminate to a wide variety of applications. Users of software employed in the SAMPL challenges number in the thousands to tens of thousands, so this will have far-reaching implications for the predictive modeling community.

Public Health Relevance

Physical methods for designing small molecule therapeutics are poised for a breakthrough, allowing molecular design for targeted treatment of diseases, personalized medicine, and rapid drug development. However, careful stress testing and improvement of these methods is necessary to make them sufficiently reliable and robust for the enormous range of problems they can potentially solve. Here, we extend our work on the SAMPL series of blind community challenges which use crowdsourcing to drive progress in this area, building automation infrastructure allowing more rapid progress and dissemination of new methodological advances.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
3R01GM124270-03S1
Application #
10165354
Study Section
Macromolecular Structure and Function D Study Section (MSFD)
Program Officer
Lyster, Peter
Project Start
2018-09-10
Project End
2022-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92617
I??k, Mehtap; Levorse, Dorothy; Rustenburg, Ariën S et al. (2018) pKa measurements for the SAMPL6 prediction challenge for a set of kinase inhibitor-like fragments. J Comput Aided Mol Des 32:1117-1138